Patent ductus arteriosus: Lack of evidence for common treatments

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 92, Issue 6, 2007, Pages

  Bose, Carl L ^a,b   Laughon, Matthew M ^b  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN; PATENT DUCTUS ARTERIOSUS; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING;

CHEMOPREVENTION; CYCLOOXYGENASE INHIBITORS; DECISION MAKING; DUCTUS ARTERIOSUS, PATENT; EVIDENCE-BASED MEDICINE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; LIGATION; REMISSION, SPONTANEOUS;

EID: 35948962834     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/adc.2005.092734     Document Type: Review

References (40)

1. Costeloe K, Hennessy E, Gibson AT, et al. The EPICure study: outcomes to discharge from hospital for infants born at the threshold of viability. Pediatrics 2000;106:659-71.
2. Marshall DD, Kotelchuck M, Young TE, et al. Risk factors for chronic lung disease in the surfactant era: a North Carolina population-based study of very low birth weight infants. North Carolina Neonatologists Association. Pediatrics 1999;104:1345-50.
3. Rojas MA, Gonzalez A, Bancalari E, et al. Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease. J Pediatr 1995;126:605-10.
4. Dollberg S, Lusky A, Reichman B. Patent ductus arteriosus, indomethacin and necrotizing enterocolitis in very low birth weight infants: a population-based study. J Pediatr Gastroenterol Nutr 2005;40:184- 8.
5. Clyman RI. Recommendations for the postnatal use of indomethacin: an analysis of four separate treatment strategies. J Pediatr 1996;128(5 Pt 1):601-7.
6. Gentile R, Stevenson G, Dooley T, et al. Pulsed Doppler echocardiographic determination of time of ductal closure in normal newborn infants. J Pediatr 1981;98:443-8.
7. Van Overmeire B, Van de Broek H, Van Laer P, et al. Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome. J Pediatr 2001;138:205-11.
8. Narayanan M, Cooper B, Weiss H, et al. Prophylactic indomethacin: factors determining permanent ductus arteriosus closure. J Pediatr 2000;136:330-7.
9. Koch J, Hensley G, Roy L, et al. Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less. Pediatrics 2006;117:1113-21.
10. Nemerofsky S, Parravicini E, Kleinman C, et al. The natural course of the ductus arteriosus in very low birthweight infants. E-PAS 2006;59:542.
11. Stefane JL, Abbasi S, Pearlman SA, et al. Closure of the ductus arteriosus with indomethacin in ventilated neonates with respiratory distress syndrome. Effects of pulmonary compliance and ventilation. Am Rev Respir Dis 1991;143:236-9.
12. Yeh TF, Luken JA, Thalji A, et al. Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus-a double-blind controlled study. J Pediatr 1981;98:137-45.
13. Krauss AN, Fatica N, Lewis BS, et al. Pulmonary function in preterm infants following treatment with intravenous indomethacin. Am J Dis Child 1989;143:78-81.
14. Farstad T, Bratlid D. Pulmonary effects of closure of patent ductus arteriosus in premature infants with severe respiratory distress syndrome. Eur J Pediatr 1994;153:903-5.
15. Van Marter LJ, Pagano M, Allred EN, et al. Rate of bronchopulmonary dysplasia as a function of neonatal intensive care practices. J Pediatr 1992;120:938-46.
16. Oh W, Poindexter BB, Perritt R, et al. Association between fluid intake and weight loss during the first ten days of life and risk of bronchopulmonary dysplasia in extremely low birth weight infants. J Pediatr 2005;147:786-90.
17. Shimada S, Kasai T, Konishi M, et al. Effects of patent ductus arteriosus on left ventricular output and organ blood flows in preterm infants with respiratory distress syndrome treatedwith surfactant. J Pediatr 1994;125:270-7.
18. Shimada S, Kasai T, Hoshi A, et al. Cardiocirculatory effects of patent ductus arteriosus in extremely low-birth-weight infants with respiratory distress syndrome. Pediatr Int 2003;45:255-62.
19. Campbell M. Patent ductus arteriosus; some notes on prognosis and on pulmonary hypertension. Br Heart J 1955;17:511-33.
20. Webb G, Gatzoulis MA. Atrial septal defects in the adult: recent progress and overview. Circulation 2006;114:1645-53.
21. Campbell M. Natural history of persistent ductus arteriosus. Br Heart J 1968;30:4-13.
22. Heymann MA, Rudolph AM, Silverman NH. Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. N Engl J Med 1976;295:530-3.
23. Fowlie PW. Intravenous indomethacin for preventing mortality and morbidity in very low birth weight infants. Cochrane Database Syst Rev 2000;2:CD000174.
24. Cooke I, Steer P, Woodgate P. Indomethacin for asymptomatic patent ductus arteriosus in preterm infants. Cochrane Database Syst Rev 2003;2:CD003745.
25. Schmidt B, Davis P, Moddemann D, et al. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med 2001;344:1966-72.
26. Knight DB. The treatment of patent ductus arteriosus in preterm infants. A review and overview of randomized trials. Semin Neonatol 2001;6:63-73.
27. Laughon MM, Simmons MA, Bose CL. Patency of the ductus arteriosus in the premature infant: is it pathologic? Should it be treated? Curr Opin Pediatr 2004;16:146-51.
28. Ohlsson A, Walia R, Shah S. Ibuprofen for the treatment of a patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2003;2:CD003481.
29. Gournay V, Roze JC, Kuster A, et al. Prophylactic ibuprofen versus placebo in very premature infants: a randomised, double-blind, placebo-controlled trial. Lancet 2004;3641939-44.
30. Shah SS, Ohlsson A. Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2006;1:CD004213.
31. Christmann V, Liem KD, Semmekrot BA, et al. Changes in cerebral, renal and mesenteric blood flow velocity during continuous and bolus infusion of indomethacin. Acta Paediatr 2002;91:440-6.
32. Watterberg KL, Gerdes JS, Cole CH, et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics 2004;114:1649-57.
33. Altridge JT, Clark R, Walker MW, et al. New insights into spontaneous intestinal perforation using a national data set: SIP is associated with early indomethacin exposure. J Perinatol 2006;26:93-9.
34. Schmidt B, Roberts RS, Fanaroff A, et al. Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: further analyses from the Trial of Indomethacin Prophylaxis in Preterms (TIPP). J Pediatr 2006;148:730-4.
35. Lee LC, Tillett A, Tulloh R, et al. Outcome following patent ductus arteriosus ligation in premature infants: a retrospective cohort analysis. BMC Pediatr 2006;6:15.
36. Moin F, Kennedy KA, Moya FR. Risk factors predicting vasopressor use after patent ductus arteriosus ligation. Am J Perinatol 2003;20: 313-20.
37. Kabra N, Schmidt B, Roberts R, et al. Surgical closure of a patent ductus arteriosus (PDA) is associated with increased neurosensory impairment in extremely low birth weight (ELBW) infants. PAS 2005;57:591.
38. Fowlie PW, Davis PG. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev 2002;3:CD000174.
39. Van Overmeire B, Allegaert K, Casaer A, et al. Prophylactic ibuprofen in premature infants: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2004;364:1945-9.
40. Silverman W. Retrolental fibroplasia: a modern parable. New York: Grune & Stratton, Inc, 1980.